

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)

**cobas**<sup>®</sup>

REF		SYSTEM
05390109 190	100	cobas e 601 cobas e 602

## English

### Intended use

Immunoassay for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide in human serum and plasma. This assay is indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.<sup>1, 2,3,4,5,6</sup> The test also aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure.<sup>7</sup> This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.<sup>8,9</sup>

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the **cobas e 601** and **cobas e 602** immunoassay analyzers.

### Summary

Left ventricular dysfunction can occur as a part of coronary heart disease, arterial hypertension, valvular disease, and primary myocardial disease. If the left ventricular dysfunction remains untreated and is progressive, the potential for mortality is high, e.g. due to sudden cardiac death.

Chronic cardiac insufficiency is a clinical syndrome caused by impairment of the cardiac pumping function. Based on the symptoms, the severity of cardiac insufficiency is classified in stages (New York Heart Association classification [NYHA] I-IV). When patients are grouped according to their NYHA classification NT-proBNP levels increase with increasing class numbers and reflect the severity of cardiac impairment.<sup>7</sup> The high sensitivity of NT-proBNP allows also the detection of mild forms of cardiac dysfunction in asymptomatic patients with structural heart disease.<sup>1,2,3,4</sup> Clinical information and imaging procedures are used to diagnose left ventricular dysfunction.<sup>10</sup>

The significance of natriuretic peptides in the control of cardiovascular system function has been demonstrated. Studies reveal that natriuretic peptides can be used for diagnostic clinical problems associated with left ventricular dysfunction.<sup>11</sup> The following natriuretic peptides have been described: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).<sup>12,13</sup>

ANP and BNP, as antagonists of the renin-angiotensin-aldosterone system, influence by means of their natriuretic and diuretic properties, the electrolyte and fluid balance in an organism.<sup>14,15</sup> In subjects with left ventricular dysfunction, serum and plasma concentrations of BNP increase, as does the concentration of the putatively inactive amino-terminal fragment, NT-proBNP.

ProBNP, comprising 108 amino acids, is secreted mainly by the ventricle and, in this process, is cleaved into physiologically active BNP (77-108) and the N-terminal fragment NT-proBNP (1-76).<sup>13</sup>

Studies indicate that NT-proBNP can be used in diagnostic and prognostic applications.<sup>7,16,17</sup> The concentration of NT-proBNP in serum or plasma correlates with the prognosis of the left ventricular dysfunction. Fisher, et al. found that congestive heart failure patients with NT-proBNP values above median had a one year mortality rate of 53 % compared to 11 % in patients below median.<sup>18</sup> In the GUSTO IV study which involved more than 6800 patients it was shown that NT-proBNP was the strongest independent predictor of one year mortality in patients with acute coronary syndrome.<sup>19</sup>

The test is also useful in assigning symptoms to cardiac or non-cardiac causes, and helps to identify subjects with left ventricular dysfunction. The European Society of Cardiology Task Force for the Diagnosis and Treatment of Chronic Heart Failure recommend in their guidelines that natriuretic peptides including NT-proBNP "may be most useful clinically as a rule out test due to consistent and very high negative predictive values".<sup>10</sup> When used with the recommended cutoff values, the Elecsys proBNP assay yields negative predictive values ranging from 97 % to 100 % depending on age and gender. Changes in NT-proBNP concentration can be used to evaluate the success of treatment in patients with left ventricular dysfunction. In addition NT-proBNP is suitable for use in assessing vascular remodelling, and therefore contributes to the establishment of individualized rehabilitation procedures.<sup>20,21</sup>

NT-proBNP also represents cardiac function and indicates increased risk in patients scheduled for potentially cardiotoxic drugs or interventions causing

fluid retention or volume overload (e.g. COX-2 inhibitors, nonsteroidal anti-inflammatory drugs).<sup>22,23,24,25,26,27,28,29,30,31,32,33</sup>

The Elecsys proBNP II STAT assay contains two monoclonal antibodies which recognize epitopes located in the N-terminal part (1-76) of proBNP (1-108).

### Test principle

Sandwich principle. Total duration of assay: 9 minutes.

- During a 9 minutes incubation, antigen in the sample (15 µL), a biotinylated monoclonal NT-proBNP-specific antibody, a monoclonal NT-proBNP-specific antibody labeled with a ruthenium complex<sup>a)</sup> and streptavidin-coated microparticles react to form a sandwich complex, which is bound to the solid phase.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

### Reagents - working solutions

The reagent rackpack is labeled as PROBNPST.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-NT-proBNP-Ab~biotin (gray cap), 1 bottle, 9 mL:  
Biotinylated monoclonal anti-NT-proBNP antibody (mouse)  
1.1 µg/mL; phosphate buffer 40 mmol/L, pH 5.8; preservative.
- R2 Anti-NT-proBNP-Ab~Ru(bpy)<sub>3</sub><sup>2+</sup> (black cap), 1 bottle, 9 mL:  
Monoclonal anti-NT-proBNP antibody (sheep) labeled with ruthenium complex 1.1 µg/mL; phosphate buffer 40 mmol/L, pH 5.8; preservative.

### Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

### Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

### Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	8 weeks

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)

cobas®

## Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-, NH<sub>4</sub>-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.

Criterion: Recovery within 90-110 % of serum value or slope 0.9-1.1 + intercept within  $\pm 2 \times$  analytical sensitivity (LDL) + coefficient of correlation  $> 0.95$ .

Stable for 3 days at 20-25 °C, 6 days<sup>34</sup> at 2-8 °C, 24 months at -20 °C.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- [REF] 05390117190, proBNP II STAT CalSet, for 4 x 1 mL
- [REF] 04917049190, PreciControl Cardiac II, for 2 x 2 mL each of PreciControl Cardiac II 1 and 2
- [REF] 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- General laboratory equipment
- **cobas e 601** or **cobas e 602** analyzer

Accessories for **cobas e 601** and **cobas e 602** analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M
- [REF] 11298500316, Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

PreClean M solution is necessary.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

## Calibration

Traceability: This method has been standardized against the proBNP II assay ([REF] 04842464).

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

**Calibration frequency:** Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

## Quality control

For quality control, use PreciControl Cardiac II.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in pmol/L or pg/mL).

Conversion factors:  $\text{pmol/L} \times 8.457 = \text{pg/mL}$   
 $\text{pg/mL} \times 0.118 = \text{pmol/L}$

## Limitations - interference

The assay is unaffected by icterus (bilirubin  $< 428 \mu\text{mol/L}$  or  $< 25 \text{ mg/dL}$ ), hemolysis (Hb  $< 0.621 \text{ mmol/L}$  or  $< 1.0 \text{ g/dL}$ ), lipemia (Intralipid  $< 17.1 \text{ mmol/L}$  or  $< 1500 \text{ mg/dL}$ ) and biotin ( $< 123 \text{ nmol/L}$  or  $< 30 \text{ ng/mL}$ ).

Samples should not be taken from patients receiving therapy with high biotin doses (i.e.  $> 5 \text{ mg/day}$ ) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of  $1500 \text{ IU/mL}$ .

There is no high-dose hook effect at NT-proBNP concentrations up to  $33400 \text{ pmol/L}$  ( $300000 \text{ pg/mL}$ ).

In vitro tests were performed on 51 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

5-35000 pg/mL or 0.6-4130 pmol/L (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as  $< 5 \text{ pg/mL}$  ( $< 0.6 \text{ pmol/L}$ ). Values above the measuring range are reported as  $> 35000 \text{ pg/mL}$  ( $> 4130 \text{ pmol/L}$ ) or up to  $70000 \text{ pg/mL}$  ( $8277 \text{ pmol/L}$ ) for 2-fold diluted samples.

### Lower limits of measurement

#### Limit of Detection (LoD)

Limit of Detection:  $5 \text{ pg/mL}$  ( $0.6 \text{ pmol/L}$ )

The Limit of Detection was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)

cobas®

corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

## Dilution

Samples with NT-proBNP concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:2 (either automatically by the **cobas e 601** and **cobas e 602** analyzers or manually). The concentration of the diluted sample must be > 1770 pmol/L or > 15000 pg/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzer, the **cobas e 601** and **cobas e 602** software automatically takes the dilution into account when calculating the sample concentration.

Dilutions of up to 1:10 may entail maximum deviations of 25 % from the theoretical value.

## Clinical data

### Interpretation of NT-proBNP values

With increasing age atherosclerosis and aging processes of the heart (e.g. fibrosis) result in cardiac dysfunction. Development of cardiac dysfunction is individually different and clinically asymptomatic in its early stages.<sup>35,36</sup> NT-proBNP levels reflect cardiac function or dysfunction respectively. With increasing age elevated levels of NT-proBNP are more frequently found in apparently healthy individuals, thus reflecting the increasing frequency of cardiac dysfunction.

NT-proBNP values need to be interpreted in conjunction with the medical history, clinical findings and other information (e.g. imaging, laboratory findings, accompanying disorders, treatment effects).<sup>35</sup>

### Cutoff values

A number of studies support a decision threshold for NT-proBNP of 125 pg/mL. NT-proBNP values < 125 pg/mL exclude cardiac dysfunction with a high level of certainty in patients with symptoms suggestive of heart failure e.g. dyspnea.<sup>37,38</sup> NT-proBNP values > 125 pg/mL may indicate cardiac dysfunction and are associated with an increased risk of cardiac complications (myocardial infarction, heart failure, death).

### Recommended cutoffs in patients with diagnosed stable chronic heart failure

Patients with stable heart failure (n = 721) were compared to the reference group (n = 2264).

ROC plot analysis at the cutoff value of 125 pg/mL showed a sensitivity of 88 %, a specificity of 92 %, a negative predictive value (NPV), and a positive predictive value (PPV) of 96.7 % and 80.6 %, respectively.

### Expected values

NT-proBNP concentrations in the reference group are shown in the following tables. The most appropriate decision threshold apparent from these distributions is 125 pg/mL.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### Reference group

The circulating NT-proBNP concentration was determined in samples from 1981 blood donors aged between 18 and 65 as well as 283 elderly patients aged between 50 and 90, both populations without known cardiac risks, symptoms or medical history.

The descriptive statistics for NT-proBNP concentrations (pg/mL) in the reference group are shown in the following table:

All						
Age (years)	N	Mean	SD	Median	95 <sup>th</sup> percentile	97.5 <sup>th</sup> percentile
18-44	1323	35.6	30.2	20.4	97.3	115
45-54	408	49.3	63.3	30.7	121	172
55-64	398	72.6	84.4	47.3	198	263
65-74	102	107	85.9	85.1	285	349
≥ 75	33	211	152	174	526	738
Total	2264	50.3	62.4	27.9	149	196

Males						
Age (years)	N	Mean	SD	Median	95 <sup>th</sup> percentile	97.5 <sup>th</sup> percentile
18-44	815	27.7	25.5	20.0	62.9	85.8
45-54	278	39.0	63.6	21.6	83.9	121
55-64	259	57.2	74.5	37.7	161	210
65-74	61	105	87.9	83.9	241	376
≥ 75	13	163	116	151	486	486
Total	1426	39.8	55.3	20.0	113	169

Females						
Age (years)	N	Mean	SD	Median	95 <sup>th</sup> percentile	97.5 <sup>th</sup> percentile
18-44	508	48.2	32.8	37.1	116	130
45-54	130	71.5	56.7	55.4	169	249
55-64	139	101	94.0	79.6	247	287
65-74	41	109	83.8	85.2	285	301
≥ 75	20	243	167	191	738	738
Total	838	68.2	69.3	47.8	177	254

In the pediatric population aged between 1 and 18 the following NT-proBNP values were obtained using the Elecsys proBNP II assay:<sup>39</sup>

Age (years)	N	NT-proBNP (ng/L)	
		75 <sup>th</sup> percentile	97.5 <sup>th</sup> percentile
1-3	13	231	320
4-6	21	113	190
7-9	32	94	145
10	11	73	112
11	69	93	317
12	21	95	186
13	23	114	370
14	18	68	363
15	24	74	217
16	24	85	206
17	24	71	135
18	12	53	115

### Correlation of NT-proBNP with NYHA classification in patients diagnosed with CHF

NT-proBNP values (pg/mL) for patients with restricted left ventricular ejection fraction (majority under therapy).

NYHA functional class				
	NYHA I	NYHA II	NYHA III	NYHA IV
N	182	250	234	35
Mean	1016	1666	3029	3465
SD	1951	2035	4600	4453
Median	342	951	1571	1707
5 <sup>th</sup> percentile	33.0	103	126	148
95 <sup>th</sup> percentile	3410	6567	10449	12188
% > 125 pg/mL	78.6	94.0	95.3	97.1

### Patients presenting acute dyspnea - ICON (International Collaborative of NT-proBNP) study<sup>40</sup>

NT-proBNP concentrations were determined in samples from 1256 patients presenting with acute shortness of breath to emergency departments at four

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)

cobas®

hospitals. This population included patients with a prior history of hypertension, coronary artery disease, myocardial infarction, heart failure, or pulmonary disease. 720 subjects were found to be suffering from acute exacerbation of heart failure, while the remainder were determined to present dyspnea due to other causes. The descriptive statistics for NT-proBNP concentrations (pg/mL) for both groups are shown in the following table:

ICON Population	Acute dyspnea without acute heart failure			Acute dyspnea with acute heart failure		
Age (years)	< 50	50-75	> 75	< 50	50-75	> 75
Mean	163	500	1209	7947	7964	10519
SD	484	1239	2703	9093	12892	15961
Median	42	121	327	5044	3512	5495
5 <sup>th</sup> percentile	5	10	24	393	416	658
25 <sup>th</sup> percentile	16	44	139	2257	1608	2154
95 <sup>th</sup> percentile	104	402	910	9825	9262	11900
97.5 <sup>th</sup> percentile	778	2101	7916	36201	29089	35183
Min.	1	1	2	196	38	17
Max.	4386	10467	15725	43177	117390	117390
N	150	281	105	33	251	436

## Result interpretation in patients presenting acute dyspnea

By using the optimal cutoffs established by the ICON study group and shown in the table below, physicians can increase the specificity and accuracy for diagnosing heart failure in patients presenting acute dyspnea in the emergent setting.

Category	Optimal cut-point pg/mL	Sensitivity %	Specificity %	PPV %	NPV %	Accuracy %
<b>Rule in cut-point</b>						
< 50 years (n = 184)	450	97	93	79	99	94
50-75 years (n = 537)	900	90	82	83	88	85
> 75 years (n = 535)	1800	85	73	92	55	83
<b>Rule out cut-point</b>						
All patients	300	99	60	77	98	83

## Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplication each for 21 days (n = 84). The following results were obtained:

cobas e 601 and cobas e 602 analyzers	Repeatability				
Sample	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%
Human serum 1	59.3	7.00	2.10	0.248	3.5

cobas e 601 and cobas e 602 analyzers	Repeatability				
Sample	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%
Human serum 2	142	16.8	2.88	0.340	2.0
Human serum 3	422	49.8	7.57	0.893	1.8
Human serum 4	935	110	17.57	2.08	1.9
Human serum 5	6552	773	133	15.7	2.0
PC CARDII <sup>b</sup> 1	130	15.34	3.09	3.32	2.4
PC CARDII2	4942	583	108	12.7	2.2

b) PC CARDII = PreciControl Cardiac II

cobas e 601 and cobas e 602 analyzers	Intermediate precision				
Sample	Mean		SD		CV
	pg/mL	pmol/L	pg/mL	pmol/L	%
Human serum 1	59.3	7.00	2.10	0.248	3.5
Human serum 2	142	16.8	3.57	0.421	2.5
Human serum 3	422	49.8	8.56	1.01	2.0
Human serum 4	935	110	23.0	2.71	2.5
Human serum 5	6552	773	153	18.0	2.3
PC CARDII1	130	15.34	3.21	0.379	2.5
PC CARDII2	4942	583	126	14.9	2.6

## Method comparison

A comparison of the Elecsys proBNP II STAT assay (y) with the Elecsys proBNP II assay (x) using clinical samples gave the following correlations (pg/mL):

Number of samples measured: 132

Passing/Bablok<sup>41</sup> Linear regression  
 $y = 0.957x - 8.03$   $y = 0.968x - 13.97$   
 $r = 0.989$   $r = 0.999$

The sample concentrations were between approximately 6 and 32800 pg/mL (approximately 0.7 and 3870 pmol/L).

## Analytical specificity

The Elecsys proBNP II STAT assay does not show any significant cross reactions with the following substances, tested with NT-proBNP concentrations of approximately 230 pg/mL and 2300 pg/mL (max. tested concentration):

Adrenomedullin (1.0 ng/mL), aldosterone (0.6 ng/mL), angiotensin I (0.6 ng/mL), angiotensin II (0.6 ng/mL), angiotensin III (1.0 ng/mL), ANP<sub>28</sub> (3.1 µg/mL), Arg-vasopressin (1.0 ng/mL), BNP<sub>32</sub> (3.5 µg/mL), CNP<sub>22</sub> (2.2 µg/mL), endothelin (20 pg/mL) NT-proANP<sub>1-30</sub> (preproANP<sub>26-55</sub>) (3.5 µg/mL), NT-proANP<sub>31-67</sub> (preproANP<sub>56-92</sub>) (1.0 ng/mL), NT-proANP<sub>79-98</sub> (preproANP<sub>104-123</sub>) (1.0 ng/mL), renin (50 ng/mL), urodilatin (3.5 µg/mL).

## Functional sensitivity

50 pg/mL (5.9 pmol/L)

The functional sensitivity is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of 20 %.

## References

- Mueller T, Gegenhuber A, Poelz W, et al. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-48.
- Prontera C, Emdin M, Zucchelli GC, et al. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)

cobas®

- 3 Pfister R, Scholz M, Wielckens K, et al. Use of NT-proBNP in routine testing and comparison to BNP. *Eur J Heart Fail* 2004;6(3):289-293.
- 4 Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. *Eur J Heart Fail* 2004;6(3):295-300.
- 5 Costello-Boerrigter LC, Redfield MM, Rodeheffer RJ, et al. NT-proBNP is superior to BNP in the detection of Left Ventricular systolic dysfunction in the community. *J Card Fail* 2004;10(4) Suppl. 4.
- 6 Fonseca C, Sarmiento PM, Minez A, et al. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. *Rev Port Cardiol* 2004;23(7-8):979-991.
- 7 Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. *Clin Endocrinol* 1997;47(3):287-296.
- 8 Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. *Lancet* 2000;355(9210):1126-1130.
- 9 Troughton RW, Frampton CM, Yandle TG, et al. Plasma Amino-Terminal B-Type Natriuretic Peptide Measured by Elecsys 2010 Assay in a Trial of Hormone-guided Treatment for Heart Failure. *Clin Chem* 2003;49(7):1212-1215.
- 10 Remme WJ, Swedberg K. The European Society of Cardiology Task Force Report: Guidelines for the diagnosis and treatment of chronic heart failure. *European Heart Journal* 2001;22:1527-1560.
- 11 Richards AM, Nicholls GM, Yandle TG, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction. *Circulation* 1998;97:1921-1929.
- 12 de Bold AJ. Atrial Natriuretic Factor: A Hormone Produced by the Heart. *Science* 1985;230:767-770.
- 13 Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. *J Lab Clin Med* 1999;134:437-444.
- 14 de Bold AJ, Boerenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial extracts in rats. *Life Sci* 1981;28:89-94.
- 15 Epstein M, Loutzenhiser R, Friedland E, et al. Relationship of Increased Plasma Atrial Natriuretic Factor and Renal Sodium Handling During Immersion-induced Central Hypervolemia in Normal Humans. *J Clin Invest* 1987;79:738-745.
- 16 The European Society of cardiology, Struthers AD. How to use natriuretic peptide levels for diagnosis and prognosis. *Eur Heart J* 1999;20:1374-1375.
- 17 Talwar S, Squire IB, Davies JE, et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. *Eur Heart J* 1999;20:1736-1744.
- 18 Fisher C, Berry C, Blue L, et al. NT proBNP Predicts Prognosis in Patients with Chronic Heart Failure. *Heart* 2003;89:879-881.
- 19 James SK, Lindahl B, Siegbahn A, et al. NT proBNP and other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients with Unstable Coronary Artery Disease. GUSTO IV Substudy. *Circulation* 2003;108:275-281.
- 20 Darbar D, Davidson NC, Gillespie N, et al. Diagnostic value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. *A J Cardiol* 1996;78:284-287.
- 21 McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. *Lancet* 1998;351:9-13.
- 22 Anderson B, Sawyer DB. Predicting and preventing the cardiotoxicity of cancer therapy. *Expert Rev Cardiovasc Ther* 2008;6(7):1023-1033.
- 23 Blankfield RP. Can natriuretic peptide levels predict the cardiovascular complications of COX-2 inhibitors and nonsteroidal anti-inflammatory drugs? *J Am Board Fam Med* 2006;19:178-182.
- 24 Heringlake M, Heide C, Bahlmann L, et al. Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-proANP, and NT-proBNP in male volunteers. *J Appl Physiol* 2004;97:173-179.
- 25 Bojunga J, Sarrazin C, Hess G, et al. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. *World J Gastroenterol* 2006;12(36):5875-5877.
- 26 Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. *Drug safety* 2006;29(7):567-586.
- 27 Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? *Diab Vasc Dis Res* 2005;2:61-66.
- 28 Giannitsis E. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. *Clin Lab* 2005;51(1-2):63-83.
- 29 Häupl T, Burmester GR, Giannitsis E, et al. N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? *Ann Rheum Dis* 2007;66(6):838-839.
- 30 Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: apilot trial. *Clin Chem* 2008;54(7):1149-1157.
- 31 European Patent 1577673 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload. Patent granted 30.07.2008.
- 32 European Patent 1849009 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of cardiac hormones for assessing the cardiovascular risk with respect to the administration of anti-inflammatory drugs. Patent granted 29.10.2008.
- 33 International patent application WO 2005/124364 assigned to F. Hoffmann-LaRoche AG and Roche Diagnostics GmbH. The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication.
- 34 Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. *Clin Chim Acta* 2003;338:107-115.
- 35 Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. *Eur Heart J* 2003;24:1710-1718.
- 36 Nielsen LS, Svanegaard J, Klitgaard NA, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnea. *Eur J Heart Fail* 2004;6:63-70.
- 37 Al-Barjas M, Nair D, Morris R, et al. How can the role of N terminal pro B Natriuretic Peptide (NT-proBNP) be optimised in heart failure screening? A prospective observational comparative study. *Eur J Heart Fail* 2004;3:51 Supplement 1.
- 38 Gustafsson F, Badskjær J, Hansen F, et al. Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography. *Heart Drug* 2003;3:141-146.
- 39 Albers S, Mir TS, Haddad M, et al. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. *Clin Chem Lab Med* 2006;44(1):80-85.
- 40 Januzzi JL, van Kimmenade R, Lainchbury J, et al. European Heart Journal Advance Access published November 17, 2005.
- 41 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

# proBNP II STAT

N-terminal pro B-type natriuretic peptide, STAT (Short Turn Around Time)



## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2014, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)

